JHOP - December 2017 Vol 7, No 4

Treatment with a regimen of pembrolizumab plus trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer was well-tolerated and had clinical benefit in those whose tumors were positive for a biomarker for pembrolizumab.
Patients aged 40 years with breast cancer who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received less invasive sentinel lymph node biopsies.
According to the results of 2 recent analyses, dose-dense or dose-intense chemotherapy reduces the risk for breast cancer recurrence and improves survival compared with standard chemotherapy regimens.
Oral chemotherapeutic agents have been available for many years, and were traditionally cytotoxic drugs, such as cyclophosphamide, methotrexate, and mercaptopurine. In recent years, oral anticancer medications are being used more often in many types of cancer.
To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy.
Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
The American Cancer Society estimates that approximately 63,990 patients will be diagnosed with renal cancer in the United States in 2017. In addition, approximately 14,400 patients are projected to die in 2017 from renal cancer. Renal cancer is one of the 10 most common malignancies in men and women in the United States. In recent years, the incidence of this disease has been on the rise.
  • Alectinib Shows Superior Outcomes versus Crizotinib in NSCLC with ALK Mutation
  • Durvalumab Use After Chemoradiotherapy Prolongs Progression-Free Survival in Stage III NSCLC
  • Olaparib Improves Progression-Free Survival in Metastatic Breast Cancer with BRCA Mutation

Results 1 - 8 of 8